Advaxis to Participate in Cervivor School

Kim Dorney to give opening keynote to cervical cancer survivors

PRINCETON, N.J., Aug. 19, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS) a clinical-stage biotechnology company developing cancer immunotherapies, is pleased to participate in Cervivor School in Louisville, Kentucky. Kim Dorney, MSN/RN, Associate Director of Clinical Operations for the upcoming AIM2CERV Phase 3 clinical study, will provide the opening keynote remarks during tonight’s welcome dinner.

Cervivor is a not-for-profit organization that provides community support, education and resources for women who have or have survived cervical cancer. Launched in 2014, Cervivor School is a weekend-long retreat led by Tamika Felder, a cervical cancer survivor and founder of Cervivor, that brings cervical cancer patients together from across the country to gain a better understanding of the science behind cervical cancer and empowers them to tell their stories in an impactful and meaningful way.

“Patients play an integral role in the drug development process and we are thankful for Tamika’s commitment to empowering cervical cancer advocates,” said Daniel J. O’Connor, president and chief executive officer of Advaxis. “We are humbled that Kim has an opportunity to connect us with this inspirational group of survivors.”

Dorney is an 18-year veteran of the biotech industry with experience working across all phases of the drug development process. She will speak to the innovative, lifesaving research happening in the immuno-oncology field and highlight the upcoming AIM2CERV trial.

AIM2CERV is a Phase 3 clinical study evaluating the safety and efficacy of Advaxis’ lead immunotherapy candidate, axalimogene filolisbac (AXAL) in patients with high-risk, locally advanced cervical cancer (HRLACC). The U.S. Food and Drug Administration (FDA) has granted AXAL orphan drug designation as well as Fast Track designation for adjuvant therapy and a Special Protocol Assessment for the Phase 3 AIM2CERV trial. The trial is set to dose its first patient this year.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology immunotherapy, AXAL, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted AXAL orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients. AXAL has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the European Medicines Agency’s Committee for Advanced Therapies. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.

Advaxis Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to: statements regarding the completion and timing of the offering of shares. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at, as well as the risks identified or incorporated by reference in the registration statement and the prospectus supplement relating to the offering. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.


Advaxis, Inc.
Greg Mayes, Executive Vice President and COO 

Media Contact:
JPA Health Communications
David Connolly